Treatment Considerations for Patients With Neuropathic Pain and Other Medical Comorbidities

Haanpää, Maija L.; Gourlay, Geoffrey K.; Kent, Joel L.; Miaskowlki, Christine; Raja, Srinivasa N.; Schmader, Kenneth E.; Wells, Christopher D.
March 2010
Mayo Clinic Proceedings;Mar2010 Supplement, Vol. 85, pS15
Academic Journal
The efficacy of drugs for neuropathic pain has been established in randomized controlled trials that have excluded patients with comorbid conditions and those taking complex medications. However, patients with neuropathic pain frequently present with complex histories, making direct application of this evidence problematic. Treatment of neuropathic pain needs to be individualized according to the cause of the pain, concomitant diseases, medications, and other individual factors. Tricyclic antidepressants (TCAs), gabapentinoids, selective noradrenergic reuptake inhibitors, and topical lidocaine are the first-line choices; if needed, combination therapy may be used. When a new drug is added, screening for potential drug interactions is recommended. The TCAs have anticholinergic adverse effects and may cause orthostatlc hypotension. They should be avoided or used cautiously in patients with cardiac conduction disturbances or arrhythmlas. Patients who lack cytochrome P450 2D6 isoenzyme activity are prone to adverse effects of TCAs and venlafaxine and have a weaker analgesic response to tramadol. A combination of several serotoninergic drugs may lead to serotonin syndrome. Risk of gastrointestinal tract bleeding is increased In patients taking selective serotonin reuptake inhibitors or venlafaxine, especially when combined with nonsteroidal anti-inflammatory drugs. Dose adjustment may be needed in patients with renal or hepatic impairment. Depending on the drug, the dose is reduced or the dosage interval lengthened. Slow titration and careful follow-up are needed. No drug is absolutely safe during pregnancy and lactation. Particular care must be exercised during the first trimester when drug dose should be as low as possible. Individual weighing of benefits and risks should guide therapeutic decisions.


Related Articles

  • Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update. Dworkin, Robert H.; O'Connor, Alec B.; Audette, Joseph; Baron, Ralf; Gourlay, Geoffrey K.; Haanpaa, Maija L.; Kent, Joel L.; Krane, Elliot J.; Lebel, Alyssa A.; Levy, Robert M.; Mackey, Sean C.; Mayer, John; Miaskowski, Christine; Raja, Srinivasa N.; Rice, Andrew S. C.; Schmader, Kenneth E.; Stacey, Brett; Stanos, Steven; Treede, Rolf-Detlef; Turk, Dennis C. // Mayo Clinic Proceedings;Mar2010 Supplement, Vol. 85, pS3 

    The Neuropathic Pain Special Interest Group of the international Association for the Study of Pain recently sponsored the development of evidence-based guidelines for the pharmacological treatment of neuropathic pain. Tricyciic antidepressants, duai reuptake inhibitors of serotonin and...

  • Duloxetine/pethidine interaction.  // Reactions Weekly;3/19/2011, Issue 1343, p16 

    The article describes a case of serotonin syndrome which developed in a 52-year-old woman following pethidine administration two days after discontinuing duloxetine.

  • Clinically Significant Drug Interactions with Newer Antidepressants. Spina, Edoardo; Trifirô, Gianluca; Caraci, Filippo // CNS Drugs;2012, Vol. 26 Issue 1, p39 

    After the introduction of selective serotonin reuptake inhibitors (SSRIs), other newer antidepressants with different mechanisms of action have been introduced in clinical practice. Because antidepressants are commonly prescribed in combination with other medications used to treat co-morbid...

  • Placenta hydrolysate/serotonin uptake inhibitors.  // Reactions Weekly;6/14/2012, Issue 1410, p33 

    The article describes the case of a 44-year-old female patient who developed reversible cerebral vasoconstriction syndrome while receiving treatment with placenta hydrolysate and selective serotonin reuptake inhibitors.

  • Bupropion/citalopram/lamotrigine/trazodone interaction.  // Reactions Weekly;Apr2014, Vol. 1495 Issue 1, p12 

    The article presents a case study of a 57-year-old man who developed acute dystonic reaction while receiving treatment with bupropion, citalopram, lamotrigine and trazodone.

  • Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract. Caraci, Filippo; Crupi, Rosalia; Drago, Filippo; Spina, Edoardo // Current Drug Metabolism;Jul2011, Vol. 12 Issue 6, p570 

    No abstract available.

  • Selective Serotonin Reuptake Inhibitors and Cytochrome P-450 Mediated Drug-Drug Interactions: An Update. Hemeryck, Alex; Belpaire, Frans M. // Current Drug Metabolism;Feb2002, Vol. 3 Issue 1, p13 

    The selective serotonin reuptake inhibitors (SSRIs) have become the most prescribed antidepressants in many countries. Although the SSRIs share a common mechanism of action, they differ substantially in their chemical structure, metabolism, and pharmacokinetics. Perhaps the most important...

  • Ischaemic optic neuropathy: 5 case reports.  // Reactions Weekly;5/7/2016, Vol. 1600 Issue 1, p190 

    An abstract of the article "SSRI-associated optic neuropathy" by M.L. Moster and others is presented.

  • Tamoxifen, SSRIs, and Breast Cancer Recurrence.  // Clinical Cardiology Alert;Sep2009 Pharmacology Watch, p1 

    The article discusses research on the drug interaction between tamoxifen and selective serotonin reuptake inhibitors (SSRI) antidepressants. It references two studies published in the "Journal of Clinical Oncology." One of the studies suggested that the risk of breast cancer recurrence is...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics